Overview

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Intrepid Therapeutics, Inc.

Treatments:

Minoxidil
Pharmaceutical Solutions